Drug · CHEMBL76
CHLOROQUINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CHLOROQUINE. Drugs and targets, record CHEMBL76. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL76
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases29
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 29Source Open Targets
See all 29 diseasesTrials159
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01103063 | Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa | Phase 3 | 2,891 | 2014-09-05 | chloroquine | Its name | ClinicalTrials.gov |
| NCT01650558 | Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi | 1,499 | 2021-05-19 | chloroquine | Its name | ClinicalTrials.gov | |
| NCT01443130 | Chloroquine for Malaria in Pregnancy | Phase 3 | 900 | 2015-10-29 | chloroquine | Its name | ClinicalTrials.gov |
| NCT01376167 | Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse | Phase 2 | 851 | 2018-04-23 | chloroquine | Its name | ClinicalTrials.gov |
| NCT00379821 | Chloroquine Alone or in Combination for Malaria in Children in Malawi | Phase 3 | 640 | 2011-07-27 | chloroquine | Its name | ClinicalTrials.gov |
| NCT00440999 | Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria | Phase 3 | 456 | 2021-09-20 | chloroquine | Its name | ClinicalTrials.gov |
| NCT00677833 | Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa | Phase 2/3 | 361 | 2014-06-26 | chloroquine | Its name | ClinicalTrials.gov |
| NCT00455403 | Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS) | 357 | 2021-06-25 | chloroquine | Its name | ClinicalTrials.gov | |
| NCT03610399 | Efficacy of 3 Regimens of Chloroquine and Primaquine for Treatment of P. Vivax Malaria, Cruzeiro do Sul, Acre, Brazil | 257 | 2021-08-09 | chloroquine | Its name | ClinicalTrials.gov | |
| NCT03952650 | Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa... | Phase 1/2 | 252 | 2022-07-12 | chloroquine | Its name | ClinicalTrials.gov |
1 to 10 of 159
See all 159 trialsComparisons in its trials28
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pyronaridine Artesunate vs Chloroquine: deaths from any cause | 2 of 228 | 0 of 228 | 456 | NCT00440999 | Trial comparisons |
| Pyronaridine Artesunate vs Chloroquine: serious adverse events | 2 of 228 | 0 of 228 | 456 | NCT00440999 | Trial comparisons |
| Azithromycin/Chloroquine (Familial Status = Neonate) vs Azithromycin/Chloroquine (Familial Status = Mother): serious adverse events | 9 of 157 | 0 of 168 | 325 | NCT01103713 | Trial comparisons |
| Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: deaths from any cause | 0 of 84 | 0 of 75 | 159 | NCT04222088 | Trial comparisons |
| Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: serious adverse events | 0 of 84 | 0 of 75 | 159 | NCT04222088 | Trial comparisons |
| Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: Adequate Clinical and Parasitological Response (ACPR) | 74 of 75 | 72 of 74 | 149 | NCT04222088 | Trial comparisons |
| Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: Early Treatment Failure (ETF) | 0 of 75 | 0 of 74 | 149 | NCT04222088 | Trial comparisons |
| Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: Late Clinical Failure (LCF) | 1 of 75 | 0 of 74 | 149 | NCT04222088 | Trial comparisons |
| Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: Late Parasitological Failure (LPF) | 0 of 75 | 2 of 74 | 149 | NCT04222088 | Trial comparisons |
| Chloroquine Subjects vs Placebo Subjects: deaths from any cause | 0 of 59 | 0 of 57 | 116 | NCT00455403 | Trial comparisons |
1 to 10 of 28
See all 28 comparisons in its trialsPapers from its trials158
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL76
GET https://conductscience.org/api/drugs/v1/CHEMBL76/diseases?page=2